Oncology Other denied as duplicate or overlapping therapy by Blue Cross Blue Shield?

For Anthem Blue Cross Blue Shield Marketplace (Individual & Commercial) members, oncology drugs administered under the medical benefit are delegated to Carelon Medical Benefits Management (formerly AIM Specialty Health) for prior authorization review. Carelon uses an evidence- and value-based approach utilizing cancer treatment pathways, provider-preferred clinical review, and enhanced reimbursement and pathway adherence reporting, covering approximately 85% of spending on cancer drugs across therapeutic and supportive drugs. Carelon Cancer Treatment Pathways are cancer treatment regimens intended to support quality cancer care and reduce unneeded variation in care and cost, developed through a rigorous process of integrating evidence-based literature with physician practice guidelines. Pathways identify a subset of regimens supported by clinical evidence and practice guidelines, selected based on clinical benefit (efficacy), safety/side effects (especially those leading to hospitalizations and impacting quality of life), strength of national guideline recommendations, and cost of regimens. Off-pathway requests are reviewed individually: the platform approves requests that align with policy and pathways, and board-certified medical oncologists and nurses consult on off-pathway requests and alert providers to enhanced reimbursement opportunities. For some health plans, requested services are reviewed in accordance with client medical policies and clinical guidelines; if a request is received that is not a Carelon Pathway regimen, it may be reviewed and authorized if determined to be medically necessary, with reference to NCCN Clinical Practice Guidelines in Oncology. Critical elements include confirming the diagnosis based on a complete evaluation including history, physical examination, relevant laboratory studies, diagnostic testing, and response to prior therapeutic intervention, with anticipated benefit outweighing potential harms. Self-administered/oral oncology drugs under the pharmacy benefit are reviewed against CarelonRx clinical criteria approved by the CarelonRx Pharmacy and Therapeutics Committee, an independent external committee of practicing physicians, pharmacists, and clinicians from leading academic medical centers with expertise in evidence-based medicine across all major clinical specialties.

- Carelon's own framework permits off-pathway approval when medically necessary: the treating oncologist determines if a Pathway regimen is the best option or whether, given the patient's unique circumstances, another regimen is a better choice, and non-Pathway requests may be authorized if determined to be medically necessary, referencing NCCN Clinical Practice Guidelines in Oncology. - Cite the specific NCCN Clinical Practice Guideline (Category 1 or 2A recommendation) supporting the requested regimen for the patient's histology, stage, and biomarker status — Carelon explicitly references NCCN as an authoritative source for medical necessity determinations. - Submit biomarker/pathology reports (e.g., NGS, IHC, FISH) confirming the targetable alteration required by the FDA label or NCCN guideline; Carelon requires confirmation of the diagnosis based on complete evaluation including review of relevant laboratory studies and diagnostic testing. - For step-therapy denials, document contraindication, intolerance, or prior failure of preferred agents; step therapy requires that the member has tried an alternative therapy first, or that the prescriber has clinically documented why the member cannot take the alternative therapy. - Demonstrate that benefit outweighs harm and delay would worsen outcomes: the anticipated benefit of the recommended intervention is likely to outweigh any potential harms, including from delay or decreased access to treatment. - Invoke clinician authority and individualization: medical necessity decisions may change as new information is provided or based on unique aspects of the patient's condition, and the treating clinician has final authority and responsibility for treatment decisions and for justifying medical necessity. - For Marketplace ACA plans, cite the ACA's essential health benefit protections and the plan's obligation to follow recognized compendia (NCCN Drugs & Biologics Compendium, AHFS, Micromedex DrugDex) for off-label oncology indications, which Carelon's pathway framework already incorporates via NCCN alignment.

## Why BCBS May Deny an Oncology Drug as "Duplicate Therapy" and How to Appeal

Blue Cross Blue Shield plans sometimes issue "duplicate therapy" denials when their utilization review system flags that a second oncology agent appears to overlap in mechanism, drug class, or indicated use with another medication already authorized or dispensed. In oncology, however, multi-agent regimens are frequently the standard of care — combining agents with different but complementary mechanisms is often what makes treatment effective. A duplicate-therapy denial in this context frequently reflects an automated coding review that lacks the clinical context your oncologist has applied.

### Why This Denial Is Appealable

Oncology combination regimens are typically grounded in recognized clinical guidelines published by organizations such as NCCN (National Comprehensive Cancer Network). If your prescribed regimen reflects guideline-concordant multi-agent therapy, the "duplicate" characterization is clinically inaccurate. Additionally, even where two agents share a class, they may have distinct mechanisms, non-overlapping toxicity profiles, or additive efficacy that justifies concurrent use — all of which your oncologist can document.

### Federal Appeal Framework

• Internal appeal: File within the timeframe stated on your BCBS denial notice. ERISA §503 full-and-fair review requires the plan to consider all clinical evidence you submit.
• External review (ACA §2719): If the internal appeal is denied, you may request independent external review, typically within four months of the final internal denial. An independent review organization makes the binding decision.
• Expedited review: In active oncology treatment, delays are often clinically significant. Request expedited review if a standard timeline would jeopardize your health; expedited external review generally resolves within 72 hours.

### Documentation to Gather

1. Oncologist letter explaining regimen rationale: A letter from your treating oncologist specifically addressing why both agents are clinically necessary — distinguishing their mechanisms, roles in the regimen, and why concurrent use is appropriate. 2. Guideline-concordance statement: Your oncologist should note which guideline organization (e.g., NCCN) and which treatment pathway supports the regimen, without citing specific version numbers. 3. Diagnosis and staging records: Pathology reports, staging workup, and biomarker results that establish the clinical picture requiring this specific regimen. 4. Prior-treatment history: A chronological summary of prior oncology treatments, responses, and progressions — establishing why the current regimen is the appropriate next step. 5. BCBS medical policy for the agents: Request the plan's written coverage criteria so you can address each point directly.

### Criteria-Mapping Approach

| Plan's Duplicate-Therapy Concern | Clinical Response | |---|---| | Agents appear to share class or indication | [Oncologist explains distinct mechanisms and roles] | | Concurrent use questioned | [Guideline-concordant regimen reference, oncologist rationale] | | Clinical necessity of both agents | [Diagnosis, staging, prior-treatment history] |

An oncologist-authored letter that directly reframes the combination as standard multi-agent care — rather than duplication — is the most persuasive element of this appeal.